Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival by body weight and anti-drug antibody status
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival by body weight and anti-drug antibody status |
| Type de publication | Journal Article |
| Year of Publication | 2015 |
| Auteurs | Ahn J-S., Jackisch C., Hegg R., Stroyakovskiy D., Melichar B., Chen S-C., Crepelle-Flechais A., Lauer S., Shing M., Pivot X. |
| Journal | ANNALS OF ONCOLOGY |
| Volume | 26 |
| Pagination | 17 |
| Date Published | DEC |
| Type of Article | Meeting Abstract |
| ISSN | 0923-7534 |